Please login to the form below

Not currently logged in
Email:
Password:

Huntsworth appoints new CEO

Huntsworth Health has appointed Neil Matheson to the role of chief executive officer

Huntsworth Health has appointed Neil Matheson to the role of chief executive officer. Matheson was formerly chief executive of the company's North American operations; in his new role, he will lead the company's global operations. Sandy Royden continues as CEO of Huntsworth Health Europe.

Matheson's appointment follows the resignation of David Rowley who was CEO for eight years. Huntsworth Plc, acquired the company that Rowley founded, PBC, in 2001, providing the platform upon which Huntsworth Health was built. Rowley's leadership contributed significantly to the growth of the company, which employs more than 400 people worldwide and has amassed £50m in revenue.

Lord Chadlington, Chief Executive of Huntsworth Plc, said: "I am confident that Neil will build energetically on the Huntsworth Health platform… and lead us forward to the next stage in our global development." 

Matheson said: "I look forward to this opportunity to grow the Huntsworth Health family of best-in-class agency brands on a global scale. We have a fantastic executive team leading our brands and the talent within those brands is unparalleled."

"Sandy Royden and her talented team at Huntsworth Health Europe have done a fantastic job of building the business into a formidable force in European healthcare communications and I know they will continue to grow the European business as a critical part of our global family," added Matheson.

Huntsworth Health has offices in Philadelphia, New York, San Francisco, and London and has access to 71 offices in 30 countries through the Huntsworth plc global network.

7th October 2009

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics